Telmisartan is effective to ameliorate metabolic syndrome in rat model &amp;ndash; a preclinical report

Cheng, Kai‐Chun; Li, Yingxiao; Chang, Wei-Ting; Kuo, Feng Yu; Chen, Zhih‐Cherng

doi:10.2147/dmso.s187092

Cited by 11 publications

(6 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lack of differences in food intake, urine output and creatinine clearance between control and losartan-treated rats observed in the current study are also in line with results of previous studies [17][18][19][20][21][22]. Interestingly, we did not observe any differences in serum concentrations and urinary excretions of the electrolytes, albumin and protein between controls and losartan-treated rats (Tables 2 and 3), in both groups.…”

Section: Discussionsupporting

confidence: 93%

Changes in the Urinary Metabolites in Losartan-Treated Spontaneously Hypertensive Rats

Azis¹,

Kamal²,

Radjeni³

et al. 2021

JCHS

View full text Add to dashboard Cite

Introduction: This study examined the association of losartan induced changes in urinary metabolomic profile with the changes in blood pressure (BP) and renin-angiotensin- aldosterone system (RAAS) in spontaneously hypertensive rats (SHR). Methods: Male SHR were administered with either 0.5 mL of distilled water (control group, n=6) or 10 mg.kg -1 of losartan (group 2, n=6) daily by oral gavage for 4 weeks. Body weight, BP, food and water intake were measured weekly. At week 4, urine was collected for urinary electrolyte analysis and metabolite profiling, after which the animals were euthanised by decapitation and blood was collected for analysis of components of RAAS and electrolyte concentrations. Urine metabolite profile of SHR was determined using proton nuclear magnetic resonance ( 1 H-NMR) spectrometry combined with multivariate data analysis. Results: At week 4, losartan- treated SHR had significantly lower BP than non-treated SHR. There were no differences in water and food intake, body weight, serum and urinary electrolyte concentrations or in their urinary excretions between the two groups. No differences were evident in the components of RAAS except that the angiotensinogen level was significantly higher in losartan-treated SHR compared to non-treated SHR. Orthogonal partial least squares discriminant analysis (OPLS-DA) showed clear separation of urinary metabolites between control and losartan-treated SHR. Losartan-treated SHR group was separated from the control group by changes in the intermediates involved in glycine, serine and threonine metabolism. Conclusion: Antihypertensive effect of losartan in SHR seems to be associated with changes in urinary metabolite profile, particularly involving the metabolism of glycine, serine and threonine.

show abstract

Section: Discussionsupporting

confidence: 93%

Changes in the Urinary Metabolites in Losartan-Treated Spontaneously Hypertensive Rats

Azis¹,

Kamal²,

Radjeni³

et al. 2021

JCHS

View full text Add to dashboard Cite

show abstract

“…Vaginal Smears were collected daily during the last 12 days of modeling and stained with Giemsa stain and evaluated by light microscope to confirm PCOS induction. After modeling, experimental (PCOS) group ( n = 50) was randomly divided into five equal groups as follows: a) PCOS group (DHEA; no treatment), b) DHEA + Telmisartan group (treated with 8 mg/kg telmisartan once daily by gastric tube for 28 days) (Cheng et al., 2018), c) DHEA + Fish oil group (treated with fish oil in a dose of 2.5 ml kg ‐1 day ‐1 once daily by gastric tube for 28 days) (Kabel, Abd Elmaaboud, & Albarraq, 2015), d) DHEA + CMC solution once daily by gastric tube for 28 days; and e) DHEA + Telmisartan +Fish oil group (treated with telmisartan concomitantly with fish oil in the above‐mentioned doses for 28 days).…”

Section: Methodsmentioning

confidence: 99%

Effect of fish oil and telmisartan on dehydroepiandrosterone‐induced polycystic ovarian syndrome in rats: The role of oxidative stress, transforming growth factor beta‐1, and nuclear factor kappa B

Kabel

Ashour

Omar

et al. 2020

Food Science & Nutrition

View full text Add to dashboard Cite

Our aim was to explore the effect of telmisartan and/or fish oil on dehydroepiandrosterone (DHEA)‐induced PCOS in rats. Sixty female rats were divided into six equal groups as follows: Control; DHEA‐induced PCOS; DHEA + Telmisartan; DHEA + Fish oil; DHEA + Carboxymethyl cellulose; and DHEA + Telmisartan +Fish oil group. Plasma sex hormones, anthropometric measurements, and the glycemic indices were measured. Tissue oxidative stress parameters and the proinflammatory cytokines were assessed. The ovaries were subjected to histopathological and electron microscopic examination. Telmisartan and/or fish oil induced significant improvement of insulin resistance with amelioration of oxidative stress and inflammation compared to PCOS group. Also, telmisartan and/or fish oil restored the hormonal levels and the anthropometric measurements to the normal values. This was significant with telmisartan/fish oil combination compared to the use of each of these agents alone. In conclusion, this combination may represent a promising hope for amelioration of PCOS.

show abstract

“…Hence, the inhibitors of AT1 receptors remain as an important drug class in managing the hypertension development. 38,39 Moreover, previous studies reported markedly reduced NPs levels in patients with MetS, highlighting the importance of these peptides for homeostatic maintenance of BP levels. 40 In that sense, beneficial effect of Sac/Val, as neprylisine/AT1 receptor inhibitors, on BP and HR values may be linked to its physiological action on cardiovascular system.…”

Section: Discussionmentioning

confidence: 94%

Sacubitril/valsartan promotes white adipose tissue browning in rats with metabolic syndrome through activation of mTORC1

Nikolic,

Jeremic,

Lazarevic

et al. 2024

BioFactors

View full text Add to dashboard Cite

In addition to their usual use in the treatment of cardiovascular disease, weak evidence is available for the potential of combined use of neprilysin inhibitor (sacubitril) and AT1 receptor antagonist (valsartan) to promote browning of white adipose tissue (WAT) in rats with metabolic syndrome (MetS). This study involved 32 male Wistar albino rats divided into four groups: CTRL—healthy control rats; ENT—healthy rats treated with sacubitril/valsartan; MS—rats with MetS; MS + ENT—rats with MetS treated with sacubitril/valsartan. After finishing the experimental protocol, different WAT depots were isolated for further analysis of molecular pathways. Molecular docking and molecular dynamics studies were used for in silico assessment of the binding affinity of sacubitril and valsartan towards subunits of mechanistic target of rapamycin complex 1 (mTORC1). Sacubitril/valsartan treatment markedly diminished morphological changes in adipose tissue, resulting in smaller lipid size and multilocular lipid droplet structure in WAT. We showed significantly higher protein expression of uncoupling protein‐1 (UCP‐1) and mTORC1 in WAT of MS + ENT rats, correlating with increased relative gene expression of browning‐related markers in tissue of rats treated with sacubitril/valsartan compared with MS group of rats. In silico analysis showed that sacubitrilat and valsartan exhibited the highest binding affinity against mTOR and mLST8, forming stable complexes with these mTORC1 subunits. The observed results confirmed strong potential of combined sacubitril/valsartan treatment to increase browning markers expression in different WAT depots in MetS condition and to form permanent complexes with mTOR and mLST8 subunits over the time.

show abstract

Telmisartan is effective to ameliorate metabolic syndrome in rat model – a preclinical report

Cited by 11 publications

References 60 publications

Changes in the Urinary Metabolites in Losartan-Treated Spontaneously Hypertensive Rats

Changes in the Urinary Metabolites in Losartan-Treated Spontaneously Hypertensive Rats

Effect of fish oil and telmisartan on dehydroepiandrosterone‐induced polycystic ovarian syndrome in rats: The role of oxidative stress, transforming growth factor beta‐1, and nuclear factor kappa B

Sacubitril/valsartan promotes white adipose tissue browning in rats with metabolic syndrome through activation of mTORC1

Contact Info

Product

Resources

About